For instance, the overexpression of FTO in acute myeloid leukemia (AML) can inhibit the m6A levels of Ankyrin repeat and SOCS box containing 2 (ASB2) and of retinoic acid receptor α (RARα) mRNA, resulting in the occurrence and progression of AML (Li et al., 2017). This evidence concerns the gene RARA and acute myeloid leukemia.